Pfizer/BioNTech COVID-19 vaccine, bivalent – Additional dose(s) in 6 months – 4 years with immunocompromise
April 28, 2023 - The FDA authorized the following uses of the Pfizer/BioNTech COVID-19 vaccine, bivalent for individuals 6 months through 4 years of age with certain types of immunocompromise who have previously received three 0.2 mL doses (Pfizer/BioNTech COVID-19 vaccine or Pfizer/BioNTech COVID-19 vaccine, bivalent): — A fourth dose administered at least 1 month following the most recent dose; — Additional doses that may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances.
Top